GC WellBeing secures $126M state loan to develop at-home plasma drug for US
What's the deal? South Korea's GC녹십자 (GC WellBeing)Dealroom has a profile for this one. Try Dealroom → has secured a US$142.5M low-interest loan from the state-backed national growth fund to develop a subcutaneous immunoglobulin (SCIG) product for the US market. The company said it was selected for the fund on October 29 and disclosed the financing on November 3.
What's the endgame? The money will go toward Phase 3 trials of a 20% high-concentration SCIG and expanded production at its Ochang plant. GC녹십자 aims to file a Phase 3 trial application with the US Food and Drug Administration next year.
Why it matters: Immunoglobulin is a plasma-derived drug that supplies antibodies to patients with weak immune systems, some of whom need lifelong treatment. SCIG can be self-administered at home, unlike intravenous products that require hours-long hospital infusions.
The backstory: GC녹십자 won FDA approval for its intravenous immunoglobulin Alyglo in 2023, a first for a Korean-made product, and its immunoglobulin exports topped $100 million in 2025. Alyglo sales hit $46 million in the third quarter of 2026, up 76.9% year on year.
What's the national growth fund? It is a public-private financing programme created to build up strategic sectors such as biotech, AI, semiconductors, and batteries, with late-stage clinical projects a priority. GC녹십자 is its seventh selected company, following firms including SK bioscienceDealroom has a profile for this one. Try Dealroom →, LigaChem Bio, and AlteogenDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The US immunoglobulin market is the world's largest at about $14.4 billion a year, but three 20% SCIG products are already on sale there. Clinical success and market entry are not guaranteed.
Chief executive officer Huh Eun-chul said the selection was "a result of recognition of our global business capabilities," adding the company would "complete an immunoglobulin portfolio spanning intravenous and subcutaneous" products (translated from Korean).
The signal: The loan shows how Seoul is using non-dilutive policy money to help domestic biotech firms turn early US wins into follow-on products — with the payoff still hinging on clinical progress and commercialisation.
Read more: news.bizwatch.co.kr
Image credit: Generated with Gemini
